| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/26/2004 | WO2002072636A8 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 02/26/2004 | WO2002067982A3 Mycobacterial vaccines |
| 02/26/2004 | WO2002066652A3 Ehrlichia ruminantium polypeptides, antigens, polynucleotides, and methods of use |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002038765A3 Dna encoding bovine immunoglobulin a inducing protein and uses therefor |
| 02/26/2004 | WO2002034782A3 Endozepine-like polypeptide nov1 and nucleic acid encoding the same |
| 02/26/2004 | WO2002033089A3 Ixodes scapularis tissue factor pathway inhibitor |
| 02/26/2004 | WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039176 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| 02/26/2004 | US20040039172 Relates to immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and method of inducing anti-HIV antibodies using such immunogen |
| 02/26/2004 | US20040039169 BASB202 polypeptides and polynucleotides encoding BASB202 polypeptides and methods for producing such polypeptides by recombinant techniques; diagnostic, prophylactic and therapeutic uses |
| 02/26/2004 | US20040039165 Clostridium difficile polypeptides and uses thereof |
| 02/26/2004 | US20040039156 Comprises fusion proteins isolated from influenza virus hemagglutinin and colony stimulating factor |
| 02/26/2004 | US20040039010 Methods for treatment of acute lymphocytic leukemia |
| 02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 02/26/2004 | US20040038922 Comprises antigen, cationic lipid e.g. DC-cholesterol, and immunostimulatory oligonucleotide; us making a vaccine capable of inducing a cytotoxic T immune response when administered parenterally |
| 02/26/2004 | US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines |
| 02/26/2004 | US20040038888 Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038878 Injectable protein formulations |
| 02/26/2004 | US20040038410 Composition for the preservation of viruses |
| 02/26/2004 | US20040038406 Nanoparticle delivery systems and methods of use thereof |
| 02/26/2004 | US20040038374 Method for accessing microbial diversity |
| 02/26/2004 | US20040038373 Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| 02/26/2004 | US20040038370 Claudin polypeptides |
| 02/26/2004 | US20040038364 Such as snake venom proteases; anticoagulants |
| 02/26/2004 | US20040038361 Novel protein kinase (NPK-110) |
| 02/26/2004 | US20040038349 Heteromultimeric TNF ligand family members |
| 02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 02/26/2004 | US20040038324 Epothilone resistant cell lines |
| 02/26/2004 | US20040038303 Comprises use of small particle with appropriate hydrophilic-lipophilic-balance value to deliver anticarcinogenic agents to cells and/or tissues; drug screening |
| 02/26/2004 | US20040038297 Masp-2,a complement-fixing enzyme, and uses for it |
| 02/26/2004 | US20040038293 Antibodies to human cd154 |
| 02/26/2004 | US20040038284 Using replication error phenotype (RER) to classify and prognose tumor disorders; immunoassay |
| 02/26/2004 | US20040038275 Human frezzled-like protein |
| 02/26/2004 | US20040038271 Novel C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds |
| 02/26/2004 | US20040038205 Modified adenoviral fiber and uses |
| 02/26/2004 | US20040038202 Comprises oligonucleotides for detection and treatment of gastrointestinal disorders in rodents; veterinary medicine |
| 02/26/2004 | US20040038196 Immunoblobulin directed against smallpox inhibitor of complement enzyme (SPICE) for preventing and treating poxviral infections |
| 02/26/2004 | US20040037854 Oral vaccines to prevent candida infection |
| 02/26/2004 | US20040037852 Intramuscular or subcutaneous injection to treat a muscle disorder without development of an extensive local hypotonicity |
| 02/26/2004 | US20040037851 Growing an isolate of fusobacterium necrophorum in a growth medium for 10-18 hours to form a culture having a count population to >/= 105 cfu/ml and terminating growth |
| 02/26/2004 | US20040037850 Incapable of expressing a functional g-protein due to a mutation in the gene encoding it |
| 02/26/2004 | US20040037849 Vaccines for cat scratch fever |
| 02/26/2004 | US20040037848 Recombinant vaccine against West Nile Virus |
| 02/26/2004 | US20040037846 Chlamydia pmp proteins, gene sequences and uses thereof |
| 02/26/2004 | US20040037845 Use of flt3-ligand in the treatment of infection |
| 02/26/2004 | US20040037844 Vaccine |
| 02/26/2004 | US20040037843 Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| 02/26/2004 | US20040037842 Compositions and methods for the therapy and diagnosis of colon cancer |
| 02/26/2004 | US20040037840 Novel therapeutic vaccine formulations |
| 02/26/2004 | US20040037838 Polypeptide with the amino acid sequence of the C-terminal part of the circumsporozoite protein of a plasmodium in which cysteine residues are oxidized along with carriers, adjuvants and biodegradable microcapsules |
| 02/26/2004 | US20040037837 For stimulating CD8 T-cell response; tuberculosis vaccines; antigen presenting cells |
| 02/26/2004 | US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors |
| 02/26/2004 | US20040037833 Comprises purified imunoglobulin polypeptide or antigen binding fragment for diagnosis of disease/cancer |
| 02/26/2004 | US20040037830 Assaying platelet factor 4 superfamily members (PF4A); interleukins; for medical diagnosis; antiinflammatory agents |
| 02/26/2004 | US20040037827 Administering antibody to integrin |
| 02/26/2004 | US20040037826 Combined use of a modulator of CD3 and a GLP-1 compound |
| 02/26/2004 | US20040037824 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037817 Deleting lympocytes and reactivating thymus via CD34-antigens and/or leutininzing hormone releasing hormone agonists (sex steroids); for alleviation of autoimmune diseases and allergies |
| 02/26/2004 | US20040037816 Graft acceptance through manipulation of thymic regeneration |
| 02/26/2004 | US20040037815 Isolation and use of solid tumor stem cells |
| 02/26/2004 | US20040037808 Methods for modulating T cell responses by manipulating a commom cytokine receptor gamma-chain |
| 02/26/2004 | US20040037805 DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of |
| 02/26/2004 | DE10231655A1 Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 02/26/2004 | DE10225139A1 Verfahren zur Identifizierung von immunreaktiven Peptiden A method for identifying immunoreactive peptides |
| 02/26/2004 | CA2854798A1 Anti-tnf-alpha antibodies in solution and uses thereof |
| 02/26/2004 | CA2535760A1 Apicomplexan pathways, inhibitiors, and drug delivery |
| 02/26/2004 | CA2535748A1 Pthrp-derived modulators of smooth muscle proliferation |
| 02/26/2004 | CA2496419A1 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 02/26/2004 | CA2496048A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/26/2004 | CA2496005A1 Use of botulinum toxin for the treatment of fine wrinkles and pore size |
| 02/26/2004 | CA2495680A1 Hepatitis c viral-like particle purification |
| 02/26/2004 | CA2495251A1 Fc.gamma.riib-specific antibodies and methods of use thereof |
| 02/26/2004 | CA2494971A1 Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| 02/26/2004 | CA2494539A1 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer |
| 02/26/2004 | CA2492930A1 Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 02/25/2004 | EP1391729A1 Antitumor antigen against htlv-1 tumor or antigen epitope thereof |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| 02/25/2004 | EP1391221A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 02/25/2004 | EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| 02/25/2004 | EP1391206A1 Pharmaceutical compositions comprising arsenic for the treatment of lymphoma |
| 02/25/2004 | EP1391202A1 Liquid drug preparations |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390517A2 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins |
| 02/25/2004 | EP1390516A1 Novel expression vectors and uses thereof |
| 02/25/2004 | EP1390512A1 A method for transfection of rna using electrical pulses |
| 02/25/2004 | EP1390505A2 Antigens of group b streptococcus and corresponding dna fragments |
| 02/25/2004 | EP1390502A2 Interferon-alpha induced gene |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390495A2 Immunostimulatory oligodeoxynucleic molecules |
| 02/25/2004 | EP1390494A2 Method for stabilising of nucleic acids |
| 02/25/2004 | EP1390474A1 Method for obtaining antigen-specific tr1 regulatory lymphocytes |